DTCC To Establish Japanese OTC Trade Repository

tokyo
Japan is following other major markets in reporting OTC trade flows to repositories.

The utility, which has been authorized by the Financial Services Agency of Japan, will cover credit, equity, foreign exchange (FX) and interest-rate derivatives. Based in Tokyo, it will begin operations ahead of the April 1 deadline set by the regulator for mandatory reporting of trades by market participants, in line with global OTC reform.

Along with other elements such as clearing through central counterparties, trade reporting is seen by regulators as a crucial aspect of reducing system risk in the OTC market. With the data, national authorities can build a picture of the previously-opaque market and identify areas that are potentially of concern.

"The launch of a Japanese trade repository is a significant and welcome development for facilitating effective OTC derivatives trade reporting in this market," says Keiko Fukuda, executive director at Morgan Stanley MUFG Securities. "It is critical that there is in place a strong infrastructure that provides market participants with the ability to submit trades for regulatory supervision in a seamless and cost-efficient manner."

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

If M&A picks up, who’s on the auction block?

Waters Wrap: With projections that mergers and acquisitions are geared to pick back up in 2025, Anthony reads the tea leaves of 25 of this year’s deals to predict which vendors might be most valuable.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here